AMRA, the international leader in body composition analysis, and Artialis, leading specialists in musculoskeletal health, have announced an alliance that will allow clinical trials for musculoskeletal disorders to benefit from AMRA’s technology.
The results of the collaboration will be analysed with the aim of identifying new, more specific biomarkers for sarcopenia.
Sarcopenia is defined as the decline of muscle structure and function in the elderly, leading to functional disability, decreased quality of life, and increased mortality. With an ageing population and over two billion people expected to be over the age of 60 by 2050, sarcopenia is becoming increasingly prevalent.
In Europe alone, it is predicted that the number of individuals with sarcopenia will rise from over 10 million in 2016 to well over 18 million in 2045 – a 72.4% increase.
Though several biomarkers have been established to help treat sarcopenia, more specific biomarkers that are sensitive to skeletal muscle changes are needed to prevent of the disease, develop new therapies, and monitor treatment efficacy.
In the development of these biomarkers, imaging data has proven valuable, with MRI offering the best resolution of all techniques. However, challenges exist. AMRA offers a solution to these, as the first company in the world to transform images from a six minute whole body MRI into 3D-volumetric fat and muscle measurements.
The automated analysis of multiple validated measurements from a single, rapid scan introduces a new standard for body composition analysis. AMRA also enables great accuracy and precision when assessing lean tissue changes, muscle fat infiltration, and overall metabolic status.
Artialis supports drug development in the field of musculoskeletal disorders, pain, and inflammation by offering complete, customised solutions for preclinical and clinical studies, from in-vitro to post-marketing clinical phase.
Artialis now joins its expertise with that of AMRA in the collaborative research of MRI-based fat and muscle measurements as comparative endpoints in clinical trials.
Tommy Johansson, Chief Executive Officer of AMRA, said: “With an aging population, we know that sarcopenia is a global health problem, one that requires a precise understanding of the disease and how it is treated. Thus we believe AMRA’s work with Artialis will be a strong asset to the community as a whole.”